一位有早期老年痴呆症的68岁的密西西比妇女正在利用LEQEMBI来减缓下降速度,强调早期诊断和家庭。 A 68-year-old Mississippi woman with early Alzheimer’s is using LEQEMBI to slow decline, emphasizing early diagnosis and family.

来自密西西比的68岁的NICU退休护士Diana “Di” Fillhart于2022年在注意到记忆失效后被诊断为轻微认知障碍,这是阿尔茨海默氏病的最早阶段。 Diana "Di" Fillhart, a 68-year-old retired NICU nurse from Mississippi, was diagnosed with mild cognitive impairment, the earliest stage of Alzheimer’s disease, in 2022 after noticing memory lapses. 她开始使用LEQEMBI治疗,LEQEMBI是经批准用于早期阿尔茨海默氏病的药物,该药物针对大脑中的氨基甲状腺瘤,并显示临床试验的认知下降速度缓慢。 She began treatment with LEQEMBI, a drug approved for early Alzheimer’s, which targets amyloid plaque in the brain and has been shown to slow cognitive decline in clinical trials. 治疗通过双周四注射进行,可能转而采用每周一次的下皮注射。 Administered via biweekly IV infusions, the treatment may transition to a weekly subcutaneous injection. 虽然LEQEMBI具有严重风险,包括大脑膨胀或出血,但Di仍然充满希望,强调早期诊断和主动护理的重要性。 While LEQEMBI carries serious risks, including brain swelling or bleeding, Di remains hopeful, emphasizing the importance of early diagnosis and proactive care. 她继续注重与家人和信仰界的时间安排,强调保持独立和联系的复原力和价值。 She continues to focus on time with her family and faith community, highlighting resilience and the value of maintaining independence and connection.